湖南海利(600731.SH):擬4.84億元建海利貴溪新區生產裝置建設項目
格隆匯1月9日丨湖南海利(600731.SH)公佈,海利貴溪化工農藥有限公司(“海利貴溪”)的安全生產許可證於2019年12月31日到期,安全生產許可證延期暫未獲得政府批准,根據公司發展及戰略規劃需要,公司擬以海利貴溪為項目實施主體,總投資48432萬元建設海利貴溪新區生產裝置建設項目,優化公司生產佈局,提高公司競爭力。
項目的主要內容:擬採用母公司湖南海利自主開發的成熟工藝,在貴溪市硫磷化工基地建設3500噸/年鄰仲丁基苯酚,1500噸/年鄰異丙基苯酚,3000噸/年丁硫克百威,1000噸/年4-TBC生產裝置及配套公用工程和設施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.